{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:41:04Z","timestamp":1790815264280,"version":"4.1.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"20","funder":[{"name":"P Koelblinger"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.2217\/fon-2017-0170","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T08:51:33Z","timestamp":1496825493000},"page":"1755-1766","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":51,"title":["A review of binimetinib for the treatment of mutant cutaneous melanoma"],"prefix":"10.1080","volume":"13","author":[{"given":"Peter","family":"Koelblinger","sequence":"first","affiliation":[{"name":"Department of Dermatology,University Hospital of Zurich,\rZurich,\rSwitzerland"},{"name":"Department of Dermatology,Paracelsus Medical University,\rSalzburg,\rAustria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Dornbierer","sequence":"additional","affiliation":[{"name":"Department of Dermatology,University Hospital of Zurich,\rZurich,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology,University Hospital of Zurich,\rZurich,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3361"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10185.x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12848"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.022"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv297"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.005"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0051"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.006"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70024-X"},{"key":"e_1_3_2_21_1","unstructured":"Array Biopharma Inc\n. Investigator's Brochure Binimetinib (MEK162) Edition 12.1 (2016)."},{"key":"e_1_3_2_22_1","volume-title":"22nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics","author":"Winski S","year":"2010","unstructured":"Winski S , AndersonD, BouhanaKet al. MEK162 (ARRY-162), a Novel MEK 1\/2 Inhibitor, Inhibits Tumor Growth Regardless of KRas\/Raf Pathway Mutations. Presented at: 22nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics. Berlin, Germany, 27 May 2010."},{"key":"e_1_3_2_23_1","volume-title":"2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics","author":"Bendell J","year":"2011","unstructured":"Bendell J , PapadopoulosK, JonesSet al. A Phase I Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors. Presented at: 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA, USA, 12\u201316 November 2011."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.10"},{"key":"e_1_3_2_25_1","volume-title":"2012 ASCO Annual Meeting","author":"Finn RS","year":"2012","unstructured":"Finn RS , JavleMM, TanBRet al. A Phase I Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer. Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1\u20135 June 2012."},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04304"},{"key":"e_1_3_2_27_1","volume-title":"European Society for Medical Oncology (ESMO) 2014 Congress","author":"Van Herpen CM","year":"2014","unstructured":"Van Herpen CM , AgarwalaSS, HauschildAet al. Overall Survival and Biomarker Results From a Phase II Study of MEK1\/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma. Presented at: European Society for Medical Oncology (ESMO) 2014 Congress. Madrid, Spain, 26\u201330 September 2014."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30180-8"},{"key":"e_1_3_2_29_1","volume-title":"Society for Melanoma Research Thirteenth International Congress","author":"Dummer R","year":"2016","unstructured":"Dummer R , AsciertoPA, GogasHJet al. Results of COLUMBUS Part 1: A Phase III Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Presented at: Society for Melanoma Research Thirteenth International Congress. Boston, MA, USA, 6\u20139 November 2016."},{"issue":"8","key":"e_1_3_2_30_1","article-title":"Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor [abstract]","volume":"72","author":"Stuart DD","year":"2012","unstructured":"Stuart DD , LiN, PoonDJet al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research72(Suppl. 8), 2012 (Abstract nr 3790).","journal-title":"Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research"},{"key":"e_1_3_2_31_1","volume-title":"HemOnc Today: Melanoma and Cutaneous Malignancies","author":"Dummer R","year":"2014","unstructured":"Dummer R , FlahertyKT, KeffordRet al. The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma. Presented at: HemOnc Today: Melanoma and Cutaneous Malignancies. New York, NY, USA, 11\u201312 April 2014."},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9007","article-title":"A Phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. [abstract]","volume":"33","author":"Sullivan RJ","year":"2015","unstructured":"Sullivan RJ , WeberJS, PatelSPet al. A Phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. [abstract]. J. Clin. Oncol.33(Suppl.), 2015 (Abstract 9007).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182372636"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139438"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024"},{"key":"e_1_3_2_36_1","volume-title":"Presented at: Society for Melanoma Research Thirteenth International Congress","author":"Infante J","year":"2016","unstructured":"Infante J , KimTM, FriedmannJet al. Safety and clinical activity of atezolizumab combined with cobimetinib in metastatic melanoma. Presented at: Society for Melanoma Research Thirteenth International Congress. Boston, MA, USA, 6\u20139 November 2016."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60398-5"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1491"},{"issue":"6","key":"e_1_3_2_39_1","first-page":"379","article-title":"Pimasertib versus dacarbazine in patients with cutaneous NRAS melanoma: a controlled, open-label Phase II trial with crossover","volume":"27","author":"Lebbe C","year":"2016","unstructured":"Lebbe C , DutriauxC, LesimpleTet al. Pimasertib versus dacarbazine in patients with cutaneous NRAS melanoma: a controlled, open-label Phase II trial with crossover. Presented at: ESMO 2016 Congress. Ann. Oncol.27(6), 379\u2013400, Copenhagen, Denmark (2016).","journal-title":"Presented at: ESMO 2016 Congress. Ann. Oncol."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834015616934"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:47Z","timestamp":1719125087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":39,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.2217\/fon-2017-0170"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0170","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}